Chiasma Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 09/15/2021)
Today's Range
50-Day Range
52-Week Range
Volume147 shs
Average Volume2.12 million shs
Market Capitalization$217.68 million
P/E RatioN/A
Dividend YieldN/A

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

Chiasma logo

About Chiasma

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.97 out of 5 stars

Medical Sector

609th out of 1,352 stocks

Pharmaceutical Preparations Industry

299th out of 665 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

Is Chiasma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Chiasma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CHMA, but not buy additional shares or sell existing shares.
View analyst ratings for Chiasma
or view top-rated stocks.

What stocks does MarketBeat like better than Chiasma?

Wall Street analysts have given Chiasma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chiasma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Chiasma's earnings last quarter?

Chiasma, Inc. (NASDAQ:CHMA) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analyst estimates of $1.80 million.
View Chiasma's earnings history

What price target have analysts set for CHMA?

3 Wall Street analysts have issued 12 month price objectives for Chiasma's shares. Their forecasts range from $12.00 to $15.00. On average, they anticipate Chiasma's share price to reach $13.50 in the next year. This suggests a possible upside of 259.0% from the stock's current price.
View analysts' price targets for Chiasma
or view top-rated stocks among Wall Street analysts.

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, Pres, CEO & Director (Age 56, Pay $827.55k)
  • Mr. Anand Varadan, Exec. VP & Chief Commercial Officer (Age 54, Pay $542.27k)
  • Mr. John Brendan Doyle, Sr. VP, CFO & Treasurer (Age 44)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 47)
  • Ms. Dawn Schottlandt CFA, VP of Investor Relations & Corp. Communications
  • Mr. Lee G. Giguere, VP, Gen. Counsel and Sec. (Age 40)
  • Mr. Derek Brown, VP of Marketing
  • Mr. Joe Lyons, Exec. Director of HR
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55)
  • Mr. David M. Schubert, Sr. VP of Regulatory & Quality

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Who are Chiasma's major shareholders?

Chiasma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.08%), Man Group plc (3.39%), Highbridge Capital Management LLC (2.25%), Millennium Management LLC (2.23%), Bruce & Co. Inc. (2.16%) and BlackRock Inc. (2.12%). Company insiders that own Chiasma stock include David M Stack, Raj Kannan, Roni Mamluk and William Ludlam.
View institutional ownership trends for Chiasma

Which major investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Ikarian Capital LLC, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Chiasma
or view top insider-selling stocks.

Which major investors are buying Chiasma stock?

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Man Group plc, Highbridge Capital Management LLC, Millennium Management LLC, Whitebox Advisors LLC, Yakira Capital Management Inc., Ergoteles LLC, Tudor Investment Corp Et Al, and Crabel Capital Management LLC. Company insiders that have bought Chiasma stock in the last two years include David M Stack, Raj Kannan, and William Ludlam.
View insider buying and selling activity for Chiasma
or or view top insider-buying stocks.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $3.76.

How much money does Chiasma make?

Chiasma has a market capitalization of $217.68 million and generates $1.11 million in revenue each year. The biotechnology company earns $-74,780,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Chiasma have?

Chiasma employs 85 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is

Where are Chiasma's headquarters?

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.